Core Framework & Diagram The Accidental Discovery of NK Cells
7 月 24, 20261 Min Read The Birth of ‘Immune Surveillance Theory’
7 月 24, 2026Your body has a force that shoots without orders
—— Its discovery rewrote immunology's foundational assumptions.
I. An experimental result that shouldn't have happened
In 1975, Rolf Kiessling at Stockholm's Karolinska Institute was studying T cells' ability to kill tumors. The experimental design was standard: take a batch of normal mice that had never been exposed to tumor, extract their lymphocytes, test whether these 'untrained' cells could kill tumor cells — the expected answer was no, because T cells need to be first activated by antigen. The result confused him for months: those 'untrained' cells killed the tumor. Not weak background noise, but significant, reproducible killing. He initially assumed experimental contamination, repeatedly washing cells, changing culture medium, replacing mice — the result persisted. In 1975, he and his colleagues published this result in the International Journal of Cancer, carefully naming this type of cell 'Natural Killer cells' — 'natural' meaning no prior activation required, inherently capable of killing.
The same year, Ronald Herberman's team at the National Institutes of Health independently reported the same discovery. Two papers published simultaneously — science began taking this anomaly seriously. Two teams, with no communication between them, simultaneously reaching the same conclusion: this is itself a signal in scientific history. When independent laboratories simultaneously see the same thing, that thing tends to be real.
2. How NK cells know who to kill
This is NK cells' most counterintuitive aspect: unlike T cells, they don't recognize specific antigens. Instead they use an entirely different logic. The core of this logic came from the 'Missing Self Hypothesis,' systematically articulated around 1986 by Klas Ljunggren and Klas Kärre. Normal cell surfaces continuously express a class of proteins called MHC-I molecules (Major Histocompatibility Complex class I). This is the cell's 'identity card' — it reports to the immune system what proteins are being synthesized inside, and T cells check this identity card to recognize infected cells. But tumor cells and virus-infected cells share a common 'survival strategy': downregulate or shut off MHC-I expression — because once MHC-I works normally, the abnormal proteins inside them will be exposed, recognized by T cells and killed. So they choose to hide their identity cards.
This strategy can fool T cells, but not NK cells. NK cells carry inhibitory receptors that specifically check for MHC-I signals: once normal MHC-I is detected, the inhibitory signal activates and NK cells stand down; once MHC-I signal is absent or abnormal, inhibition is lifted, NK cells move in and kill. NK cell surfaces simultaneously carry activating receptors (like NKG2D, recognizing stress signal molecules expressed by tumor and infected cells) and inhibitory receptors (like the KIR family, recognizing MHC-I). When activating signals exceed the inhibitory signal threshold, NK cells trigger attack. This is a precise analogical computation — not a simple switch, but continuous signal comparison.
|
NK cells aren't searching for 'enemy markers' — they're checking whether 'teammates' identity cards are intact. Cells that have lost their protective signal are attack targets. This is immunology's first important case of 'reverse logic.' |
3. NK cells' arsenal: three killing mechanisms
Perforin-Granzyme system: after NK cells identify a target, they release perforin (punching holes in the target cell membrane) and granzymes (entering through those holes to trigger programmed death). The entire process takes only minutes — NK cells' primary, fastest killing method. Death receptor pathway: NK cell surfaces express TRAIL and FasL ligands, binding with death receptors on target cell surfaces, directly inducing target cell apoptosis — this pathway is particularly effective against some tumor cells resistant to perforin. ADCC (Antibody-Dependent Cellular Cytotoxicity): when antibodies have labeled target cells, NK cells can identify these labeled targets through CD16 receptors and kill them directionally. This is also one of the important mechanisms of certain monoclonal antibody therapies (like rituximab for B-cell lymphoma, trastuzumab for HER2-positive breast cancer) — these drugs not only directly block tumor growth signals but also recruit NK cells to eliminate labeled tumor cells. Beyond direct killing, NK cells secrete large amounts of interferon-γ (IFN-γ) and TNF-α, activating nearby macrophages and dendritic cells, coordinating larger-scale immune responses. It is simultaneously assassin, intelligence agent, and commander.
4. NK cells and T cells: complementary not competing
NK cells and cytotoxic T cells (CTL) can both kill tumors, using similar weapons (perforin-granzyme), but their timing and recognition logic are completely different. T cells need one to two weeks of activation time (antigen presentation, clonal expansion), relying on precise antigen recognition — advantage: precise targeting; disadvantage: slow, and tumor cells can evade by downregulating MHC-I. NK cells need almost no activation time, relying on absent MHC-I signals — advantage: fast, and they can precisely attack those tumor cells trying to hide from T cells by downregulating MHC-I. These two systems form complementary defense: if tumor cells downregulate MHC-I to evade T cells, they activate NK cells; if they upregulate MHC-I to suppress NK cells, they expose themselves to T cells. This is an evolutionary double encirclement — tumor cells are caught in a dilemma over MHC-I expression.
5. After age 40: what's happening to your NK cells
NK cells are among the immune system's members most sensitive to age. As age increases, NK cell numbers in peripheral blood may actually increase — but this is a deceptive figure. These increased NK cells have continuously declining function: their perforin content decreases, cytotoxicity weakens, cytokine secretion capacity drops, and ability to migrate to tumor sites retreats. Related research shows NK cell activity decline closely correlates with rising cancer incidence in the elderly. NK cells are one of the main forces automatically clearing early cancerous cells from your body every day. Once this force's combat capacity declines, early cancer cell clearance efficiency drops, creating conditions for tumors to enter the 'immune editing' equilibrium stage. Regular moderate-intensity exercise (150 minutes per week) is currently the most evidence-supported NK cell activity maintenance method. A 2022 meta-analysis showed long-term exercisers' NK cell cytotoxicity is significantly higher than sedentary populations, with differences of twenty to forty percent. Exercise's impact on NK cells includes: acute exercise mobilizing NK cells from bone marrow and spleen into blood (numbers temporarily rising three to four times), and long-term exercise causing NK cell functional reprogramming (expressing more activating receptors, secreting more IFN-γ).
6. NK cell research: present and future
NK cell therapy is entering clinical practice in multiple forms. Autologous NK cell infusion: extracting NK cells from a patient's own blood, expanding in vitro then reinfusing, for blood tumor adjuvant treatment. Allogeneic NK cell therapy: obtaining NK cells from healthy donors, activating and modifying them for treatment. Compared to CAR-T, allogeneic NK cell infusion has lower graft-versus-host disease (GvHD) risk — because NK cells don't recognize 'non-self' through TCR; their killing targets are cells with 'absent self signal,' not tissue compatibility differences between donor and recipient. CAR-NK cells: applying CAR technology to NK cells, giving them both NK cells' natural killing power and CAR-T's targeted precision. In 2020, the New England Journal of Medicine reported the first CAR-NK clinical results for CD19-positive blood tumors: eight of eleven patients showed remission, with no severe CRS or GvHD observed — one of the most exciting early data points in current tumor immunology.
Frequently Asked Questions